Allogeneic Stem Cell Therapy for Acute Ischemic Stroke

Researchers assessed the efficacy and safety of MultiStem when administered within 18 to 36 hours of ischemic stroke onset via the Treatment Evaluation of Acute Stroke Using Regenerative Cells (TREASURE) multicenter, double-blind, parallel-group, placebo-controlled Phase II/III randomized clinical trial.